205 related articles for article (PubMed ID: 9514177)
1. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
Mehta JL; Chen L; Nichols WW; Mattsson C; Gustafsson D; Saldeen TG
J Cardiovasc Pharmacol; 1998 Mar; 31(3):345-51. PubMed ID: 9514177
[TBL] [Abstract][Full Text] [Related]
2. Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.
Elg M; Börjesson I; Carlsson S
Biopharm Drug Dispos; 2003 Sep; 24(6):251-7. PubMed ID: 12973822
[TBL] [Abstract][Full Text] [Related]
3. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
Mattsson C; Björkman JA; Abrahamsson T; Nerme V; Schatteman K; Leurs J; Scharpé S; Hendriks D
Thromb Haemost; 2002 Apr; 87(4):557-62. PubMed ID: 12008935
[TBL] [Abstract][Full Text] [Related]
4. Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog.
Cousins GR; Friedrichs GS; Sudo Y; Rebello SS; Rote WE; Vlasuk GP; Nolan TG; Mendoza C; Lucchesi BR
Circulation; 1996 Oct; 94(7):1705-12. PubMed ID: 8840864
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
[TBL] [Abstract][Full Text] [Related]
6. Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.
Chen L; Nichols WW; Mattsson C; Teger-Nilsson AC; Saldeen TG; Mehta JL
J Pharmacol Exp Ther; 1996 Jun; 277(3):1276-83. PubMed ID: 8667188
[TBL] [Abstract][Full Text] [Related]
7. CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury.
Rebello SS; Miller BV; Basler GC; Lucchesi BR
J Cardiovasc Pharmacol; 1997 Feb; 29(2):240-9. PubMed ID: 9057074
[TBL] [Abstract][Full Text] [Related]
8. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
[TBL] [Abstract][Full Text] [Related]
9. Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery.
Rübsamen K; Kirchengast M
Coron Artery Dis; 1998; 9(1):35-42. PubMed ID: 9589189
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857.
Rübsamen K; Hornberger W; Kirchengast M
Thromb Haemost; 1995 Nov; 74(5):1353-60. PubMed ID: 8607122
[TBL] [Abstract][Full Text] [Related]
11. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.
Gustafsson D; Antonsson T; Bylund R; Eriksson U; Gyzander E; Nilsson I; Elg M; Mattsson C; Deinum J; Pehrsson S; Karlsson O; Nilsson A; Sörensen H
Thromb Haemost; 1998 Jan; 79(1):110-8. PubMed ID: 9459334
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
Fager G; Cullberg M; Eriksson-Lepkowska M; Frison L; Eriksson UG
Eur J Clin Pharmacol; 2003 Aug; 59(4):283-9. PubMed ID: 12845508
[TBL] [Abstract][Full Text] [Related]
13. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Johansson LC; Frison L; Logren U; Fager G; Gustafsson D; Eriksson UG
Clin Pharmacokinet; 2003; 42(4):381-92. PubMed ID: 12648028
[TBL] [Abstract][Full Text] [Related]
14. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
15. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Elg M; Carlsson S; Gustafsson D
Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
Eriksson UG; Mandema JW; Karlsson MO; Frison L; Gisleskog PO; Wählby U; Hamrén B; Gustafsson D; Eriksson BI
Clin Pharmacokinet; 2003; 42(7):687-701. PubMed ID: 12844328
[TBL] [Abstract][Full Text] [Related]
17. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
18. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Elg M; Gustafsson D; Deinum J
Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis.
Nicolini FA; Lee P; Malycky JL; Lefkovits J; Kottke-Marchant K; Plow EF; Topol EJ
Blood Coagul Fibrinolysis; 1996 Jan; 7(1):39-48. PubMed ID: 8845461
[TBL] [Abstract][Full Text] [Related]
20. Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model.
Scherstén F; Wahlund G; Björnheden T; Carlsson S; Mattsson C; Grip L
Blood Coagul Fibrinolysis; 2003 Apr; 14(3):235-41. PubMed ID: 12695745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
